Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

Detalles Bibliográficos
Autores principales: Caporali, Roberto, Ravasio, Roberto, Raimondo, Paola, Salaffi, Fausto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AboutScience 2022
Materias:
Erratum
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768591/
https://www.ncbi.nlm.nih.gov/pubmed/36628313
http://dx.doi.org/10.33393/grhta.2022.2383
_version_ 1784854204113747968
author Caporali, Roberto
Ravasio, Roberto
Raimondo, Paola
Salaffi, Fausto
author_facet Caporali, Roberto
Ravasio, Roberto
Raimondo, Paola
Salaffi, Fausto
author_sort Caporali, Roberto
collection PubMed
description
format Online
Article
Text
id pubmed-9768591
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher AboutScience
record_format MEDLINE/PubMed
spelling pubmed-97685912023-01-09 Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy Caporali, Roberto Ravasio, Roberto Raimondo, Paola Salaffi, Fausto Glob Reg Health Technol Assess Erratum AboutScience 2022-02-17 /pmc/articles/PMC9768591/ /pubmed/36628313 http://dx.doi.org/10.33393/grhta.2022.2383 Text en https://creativecommons.org/licenses/by-nc/4.0/Global & Regional Health Technology Assessment - ISSN 2283-5733 - www.aboutscience.eu/grhta (http://www.aboutscience.eu/grhta) © 2022 The Authors. This article is published by AboutScience and licensed under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). Commercial use is not permitted and is subject to Publisher’s permissions. Full information is available at www.aboutscience.eu (http://www.aboutscience.eu)
spellingShingle Erratum
Caporali, Roberto
Ravasio, Roberto
Raimondo, Paola
Salaffi, Fausto
Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
title Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
title_full Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
title_fullStr Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
title_full_unstemmed Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
title_short Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy
title_sort erratum in: cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe rheumatoid arthritis in italy
topic Erratum
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9768591/
https://www.ncbi.nlm.nih.gov/pubmed/36628313
http://dx.doi.org/10.33393/grhta.2022.2383
work_keys_str_mv AT caporaliroberto erratumincostperresponderforupadacitinibvsabataceptinpatientswithmoderatetosevererheumatoidarthritisinitaly
AT ravasioroberto erratumincostperresponderforupadacitinibvsabataceptinpatientswithmoderatetosevererheumatoidarthritisinitaly
AT raimondopaola erratumincostperresponderforupadacitinibvsabataceptinpatientswithmoderatetosevererheumatoidarthritisinitaly
AT salaffifausto erratumincostperresponderforupadacitinibvsabataceptinpatientswithmoderatetosevererheumatoidarthritisinitaly

Ejemplares similares